人類胰島素市場規模、佔有率和成長分析（按產品、類型、品牌、給藥裝置、糖尿病和地區）- 2025-2032 年產業預測

2023 年人類胰島素市場規模價值 193.7 億美元，預計將從 2024 年的 202.8 億美元成長到 2032 年的 292.9 億美元，預測期內（2025-2032 年）的複合年成長率為 4.7%。

人類胰島素市場對於糖尿病管理至關重要，為數百萬受第 1 型和第 2 型糖尿病影響的患者提供基本治療。國際糖尿病聯盟預測，到2045年，患有糖尿病的成年人數量將從2019年的4.63億增加到7億，預計將大幅增加對胰島素的需求並推動市場成長。製造技術的發展，特別是重組DNA技術，使得胰島素更安全、更有效，也提高了病人的接受度。醫療保健組織、政府和非政府組織之間的合作旨在提高人們的認知並改善獲得胰島素的機會，特別是在低收入地區。然而，高昂的製造成本和監管挑戰阻礙了其普及。向模擬胰島素的轉變、筆和幫浦等創新輸送設備的日益普及，再加上人工智慧的整合，是提高治療依從性和擴大市場的一些顯著趨勢。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

人類胰島素市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• HI 藥物
• HI 輸送裝置

人類胰島素市場規模（按類型和複合年成長率） (2025-2032)

• 市場概況
• 胰島素類似物和生物相似藥
  • 立即見效
  • 長效
  • 預混合料
• HI 生物製劑
  • 短效
  • 中效
  • 預混合料

人類胰島素市場規模（按品牌和複合年成長率） (2025-2032)

• 市場概況
• HI 類似物和生物相似藥
  • 來得時
  • 諾和Rapid/NovoLog
  • Humalog
  • 其他品牌
• HI 生物製劑
  • Actrapid、Insulatard、Mixtard
  • 優泌林
  • 旅館老闆

人類胰島素市場規模（按輸送裝置和複合年成長率） (2025-2032)

• 市場概況
• 筆
  • 可重複使用的
  • 一次性的
• 筆針
  • 標準
  • 安全
• 注射器

人類胰島素市場規模（按糖尿病類型和複合年成長率） (2025-2032)

• 市場概況
• 1 型糖尿病
• 2 型糖尿病

人類胰島素市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Biocon Limited（India）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• AstraZeneca（United Kingdom）
• Boehringer Ingelheim（Germany）
• Tonghua Dongbao Pharmaceutical Co., Ltd.（China）
• Wockhardt（India）
• Julphar（United Arab Emirates）
• Oramed Pharmaceuticals Inc.（United States）
• Adocia（France）
• MannKind Corporation（United States）
• Gan & Lee Pharmaceuticals（China）
• Ypsomed（Switzerland）
• Medtronic（Ireland）
• Dexcom（United States）
• Insulet Corporation（United States）
• Senseonics Holdings, Inc.（United States）

結論和建議

Human Insulin Market size was valued at USD 19.37 billion in 2023 and is poised to grow from USD 20.28 billion in 2024 to USD 29.29 billion by 2032, growing at a CAGR of 4.7% during the forecast period (2025-2032).

The human insulin market is crucial for diabetes management, providing essential treatment to millions impacted by type 1 and type 2 diabetes. With the International Diabetes Federation projecting an increase from 463 million diabetic adults in 2019 to 700 million by 2045, the demand for insulin is expected to rise significantly, driving market growth. Advances in production techniques, particularly recombinant DNA technology, have led to the development of safer and more effective insulin, enhancing patient acceptance. Collaborations among healthcare organizations, governments, and NGOs aim to raise awareness and improve insulin accessibility, especially in low-income regions. However, high production costs and regulatory challenges hinder affordability. The shift towards analog insulins and the rising popularity of innovative delivery devices like pens and pumps, supplemented by AI integration, are notable trends in enhancing treatment adherence and market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Human Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Human Insulin Market Segments Analysis

Global Human Insulin Market is segmented by Product, Type, Brand, Delivery Devices, Diabetes and region. Based on Product, the market is segmented into HI Drugs and HI Delivery Devices. Based on Type, the market is segmented into Insulin Analogs and Biosimilars and HI Biologics. Based on Brand, the market is segmented into HI Analogs and Biosimilars and HI Biologics. Based on Delivery Devices, the market is segmented into Pens, Pen Needles and Syringes. Based on Diabetes, the market is segmented into Type I Diabetes and Type II Diabetes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Human Insulin Market

The expanding incidence of diabetes globally serves as a critical catalyst for the human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, with predictions forecasting that this figure could soar to 700 million by 2045. This escalating diabetic population intensifies the need for insulin, thereby propelling market growth. Notably, nations such as China and India have experienced a notable rise in diabetes cases, attributed to shifts in lifestyle and dietary practices, which in turn has spurred an increased requirement for human insulin to manage these conditions effectively.

Restraints in the Human Insulin Market

The human insulin market faces several constraints primarily due to regulatory challenges and patent protections that limit competition and market entry. The process of acquiring regulatory approvals for new insulin products or biosimilars is demanding, necessitating thorough testing and adherence to strict guidelines, which can delay product availability. Furthermore, patent exclusivity on specific insulin formulations restricts the emergence of generic alternatives, thereby limiting choices for patients and hindering overall market expansion. For example, the exclusivity surrounding particular long-acting insulin analogs has effectively stifled the introduction of biosimilar options in the marketplace, exacerbating these constraints and impacting accessibility.

Market Trends of the Human Insulin Market

The Human Insulin market is currently experiencing a significant shift towards analog insulin formulations, driven by their superior benefits in diabetes management. Unlike traditional human insulin, which has limitations in terms of onset and duration, analog insulins provide rapid action and enhanced glycemic control, leading to improved patient outcomes. The rising adoption of long-acting analogs such as insulin glargine (Lantus) and insulin detemir (Levemir) has reshaped market dynamics, capturing substantial market share due to their favorable pharmacokinetic profiles. This trend underscores the growing preference among healthcare professionals and patients for precise insulin therapies, marking a transformative phase in diabetes treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Human Insulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• HI Drugs
• HI Delivery Devices

Global Human Insulin Market Size by Type & CAGR (2025-2032)

• Market Overview
• Insulin Analogs and Biosimilars
  • Rapid-acting
  • Long-acting
  • Premixed
• HI Biologics
  • Short-acting
  • Intermediate-acting
  • Premixed

Global Human Insulin Market Size by Brand & CAGR (2025-2032)

• Market Overview
• HI Analogs and Biosimilars
  • Lantus
  • NovoRapid/Novolog
  • Humalog
  • Other Brands
• HI Biologics
  • Actrapid, Insulatard, and Mixtard
  • Humulin
  • Insuman

Global Human Insulin Market Size by Delivery Devices & CAGR (2025-2032)

• Market Overview
• Pens
  • Reusable
  • Disposable
• Pen Needles
  • Standard
  • Safety
• Syringes

Global Human Insulin Market Size by Diabetes & CAGR (2025-2032)

• Market Overview
• Type I Diabetes
• Type II Diabetes

Global Human Insulin Market Size & CAGR (2025-2032)

• North America (Product, Type, Brand, Delivery Devices, Diabetes)
  • US
  • Canada
• Europe (Product, Type, Brand, Delivery Devices, Diabetes)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Brand, Delivery Devices, Diabetes)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Brand, Delivery Devices, Diabetes)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Brand, Delivery Devices, Diabetes)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations